| Identification | Back Directory | [Name]
ACT-246475 | [CAS]
1159500-34-1 | [Synonyms]
ACT-246475
Selatogrel
((R)-3-(4-(butoxycarbonyl)piperazin-1-yl)-2-(6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-3-oxopropyl)phosphonic acid(WXG03500)
1-Piperazinecarboxylic acid, 4-[(2R)-2-[[[6-[(3S)-3-methoxy-1-pyrrolidinyl]-2-phenyl-4-pyrimidinyl]carbonyl]amino]-1-oxo-3-phosphonopropyl]-, 1-butyl ester | [Molecular Formula]
C28H39N6O8P | [MDL Number]
MFCD30738748 | [MOL File]
1159500-34-1.mol | [Molecular Weight]
618.62 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
1.38±0.10(Predicted) | [color ]
Light yellow to yellow | [InChIKey]
FYXHWMQPCJOJCH-GMAHTHKFSA-N | [SMILES]
N1(C(OCCCC)=O)CCN(C(=O)[C@@H](NC(C2C=C(N3CC[C@H](OC)C3)N=C(C3=CC=CC=C3)N=2)=O)CP(O)(O)=O)CC1 |
| Hazard Information | Back Directory | [Uses]
((R)-3-(4-(butoxycarbonyl)piperazin-1-yl)-2-(6-((S)-3-methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carboxamido)-3-oxopropyl)phosphonic Acid is a useful research chemical compound used in the preparation of P2Y12 Receptor Antagonists. | [in vivo]
Selatogrel (0-0.1 mg/kg, i.v., single dosage) dose-dependently blocks thrombus formation in the wistar rat FeCl3 model and causes less surgical blood loss[1]. | Animal Model: | FeCl3 induced arterial injury in wistar rats[1] | | Dosage: | 0-0.1 mg/kg | | Administration: | i.v., 5 minutes before arterial injury | | Result: | Prevented the FeCl3-induced thrombotic occlusions in a dose-dependent manner with minimal observed surgical blood loss of 0.4 g. |
|
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|